Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

• Status: Withdrawn
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel; Saracatinib

Criteria

Inclusion Criteria:

• Japanese patients with non small cell lung cancer or epithelial ovarian cancer

• Must be suitable for treatment with carboplatin and paclitaxel

• Relatively good overall health other than cancer

Exclusion Criteria:

• Poor bone marrow function (not producing enough blood cells).

• Poor liver or kidney function.

• Patients unable to discontinue drugs known to be potent inhibitors or inducers of CYP3A4 within 2 weeks prior to registration